Novartis Pushes Dermatology Momentum By Licensing Atopic Dermatitis MAb
Novartis is hoping to use its considerable Cosentyx sales slipstream and internal dermatology engine to develop its next skin success by licensing-in a novel antibody against IL-17C from Galapagos and MorphoSys.
You may also be interested in...
Lilly/Incyte’s JAK inhibitor baricitinib is the first of its class to report positive Phase III data in atopic dermatitis. But will the dosing worries of Olumiant’s rheumatoid arthritis indication spoil the party?
Biopharma financing reached $14.6 billion in the third quarter, a 15% increase over Q2, while merger and acquisitions, at $7.7 billion (the lowest quarter of the year so far), showed a sharp decline. Alliance value reached $20.3 billion, far exceeding the $13.8 billion from Q2.
Deal through Kite Pharma subsidiary focuses on developing gamma delta T-cell receptor therapies. Sanofi inks SHP2 cancer collaboration with Revolution, while Vical considers its strategic options.